FDAapproval54% confidence
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (lung cancer) as Sichuan Baili Pharmaceutical.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Non-small Cell Lung Cancer
- Sub-indication
- Lung Cancer
Related signal: Phase II Study of BL-B01D1 with PD-1 Antibody in Advanced Lung Cancer and Other Tumors